Evotec SE (NASDAQ:EVO) Q3 2024 Earnings Call Transcript
Operator: Ladies and gentlemen, welcome to the Evotec SE Quarterly Statement Nine Months 2024 Capital Market Briefing Conference Call. I am Sachin, the Chorus Call Operator.
Eaton Vance Ohio Municipal Income Trust (EVO)
Market is closed
Hedge Fund Popularity
Hedge Fund Holdings
Filing Period:
Last updated on based on SEC 13F filings Last update:
| No. | Hedge Fund | Shares | Value | Activity | % Port |
|---|---|---|---|---|---|
| 1. | Saba Capital Boaz Weinstein | 0 | $0 | -100% | 0% |
| 2. | Mariner Investment Group William Michaelcheck | 0 | $0 | -100% | 0% |
Insider Trading: Purchases See All
| Insider | Price | Amount | Relationship | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $12.83 | 92 | Large Shareholder | 392 | 2011-10-18 | Filing | |
| $12.82 | 200 | Large Shareholder | 300 | 2011-10-18 | Filing | |
| $12.79 | 100 | Large Shareholder | 100 | 2011-10-18 | Filing |
Insider Trading: Sales See All
| Insider | Price | Amount | Relationship | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $12.77 | 100 | Large Shareholder | 0 | 2011-10-18 | Filing | |
| $12.76 | 200 | Large Shareholder | 100 | 2011-10-18 | Filing | |
| $12.72 | 92 | Large Shareholder | 300 | 2011-10-18 | Filing |
Institutional Investors' Holdings
News See All
Evotec SE (NASDAQ:EVO) Q2 2024 Earnings Call Transcript
Operator: Ladies and gentlemen, welcome to the Evotec SE Half Year Report 2024 Conference Call. I am Udith, the Chorus Call Operator.
Evotec SE (NASDAQ:EVO) Q1 2024 Earnings Call Transcript
Operator: Ladies and gentlemen, welcome to the Evotec SE Quarterly Statement Q1 2024 Conference Call. I am Sandra, the chorus call operator.
Evotec SE (NASDAQ:EVO) Q4 2023 Earnings Call Transcript
Evotec SE misses on earnings expectations. Reported EPS is $-0.05 EPS, expectations were $-0.03333.
Evotec SE (NASDAQ:EVO) Q3 2023 Earnings Call Transcript
Werner Lanthaler: Welcome to our -- good morning. Good afternoon. Welcome to our Q3 Call. Resilient into the Future of Biopharma R&D.
Does Evotec SE (EVO) Have Good Long-Term Growth Prospects?
Brown Capital Management, an investment management company, released its “The Brown Capital Management International Small Company Strategy” Q3 2022 investor letter.
10 Best Low Price Pharma Stocks To Buy Now
The global pharmaceuticals market was forecasted to grow from $1454.66 billion in 2021 to $1587.05 billion in 2022 at a compound annual growth rate (CAGR) of 9.1%.
5 Best Drug Stocks To Buy Now
Evotec SE (NYSE:EVO) is a German drug discovery, pharmaceutical, and biotechnology company that produces drug candidates for diabetes, fibrosis, infectious diseases, CNS diseases, oncology, pain and inflammation...
Billionaire Hedge Funds
